Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
European Journal of Nuclear Medicine and Molecular Imaging
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 1/2013

01.07.2013 | Original Article

Influence of androgen deprivation therapy on choline PET/CT in recurrent prostate cancer

verfasst von: Rutger J. Dost, Andor W. J. M. Glaudemans, Anthonius J. Breeuwsma, Igle J. de Jong

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Sonderheft 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Recurrent prostate cancer is usually treated by combining radiotherapy and androgen deprivation therapy. To stage the cancer, choline positron emission tomography (PET)/CT can be performed. It is generally thought that androgen deprivation therapy does not influence choline PET/CT. In this article we focus on the molecular backgrounds of choline and androgens, and the results of preclinical and clinical studies performed using PET/CT.

Methods

Using PubMed, we looked for the relevant articles about androgen deprivation therapy and choline PET/CT.

Results

During ADT, a tendency of decreased uptake of choline in prostate cancer was observed, in particular in hormone-naïve patients.

Conclusion

We conclude that in order to prevent false-negative choline PET/CT scans androgen deprivation should be withheld prior to scanning, especially in hormone-naïve patients.
Literatur
1.
2.
Bauman G, Belhocine T, Kovacs M, Ward A, Beheshti M, Rachinsky I. 18F-fluorocholine for prostate cancer imaging: a systematic review of the literature. Prostate Cancer Prostatic Dis 2012;15(1):45–55.PubMedCrossRef
3.
Souvatzoglou M, Weirich G, Schwarzenboeck S, Maurer T, Schuster T, Bundschuh RA, et al. The sensitivity of [11C]choline PET/CT to localize prostate cancer depends on the tumor configuration. Clin Cancer Res 2011;17(11):3751–9.PubMedCrossRef
4.
Walsh PC. Physiologic basis for hormonal therapy in carcinoma of the prostate. Urol Clin North Am 1975;2(1):125–40.PubMed
5.
Limonta P, Montagnani Marelli M, Moretti RM. LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action. Expert Opin Investig Drugs 2001;10(4):709–20.PubMedCrossRef
6.
Abrahamsson PA. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Eur Urol 2010;57(1):49–59.PubMedCrossRef
7.
Shelley MD, Kumar S, Coles B, Wilt T, Staffurth J, Mason MD. Adjuvant hormone therapy for localised and locally advanced prostate carcinoma: a systematic review and meta-analysis of randomised trials. Cancer Treat Rev 2009;35(7):540–6.PubMedCrossRef
8.
McLeod DG, Iversen P, See WA, Morris T, Armstrong J, Wirth MP, et al. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 2006;97(2):247–54.PubMedCrossRef
9.
Shelley MD, Kumar S, Wilt T, Staffurth J, Coles B, Mason MD. A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treat Rev 2009;35:9–17.PubMedCrossRef
10.
Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev 2006;4:CD006019.PubMed
11.
van der Kwast TH, Lopes C, Santonja C, Pihl CG, Neetens I, Martikainen P, et al. Guidelines for processing and reporting of prostatic needle biopsies. J Clin Pathol 2003;56(5):336–40.PubMedCrossRef
12.
Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009;360(24):2516–27.PubMedCrossRef
13.
Bathen TF, Sitter B, Sjøbakk TE, Tessem MB, Gribbestad IS. Magnetic resonance metabolomics of intact tissue: a biotechnological tool in cancer diagnostics and treatment evaluation. Cancer Res 2010;70:6692–6.PubMedCrossRef
14.
Li Z, Vance DE. Phosphatidylcholine and choline homeostasis. J Lipid Res 2008;49(6):1187–94.PubMedCrossRef
15.
Kennedy EP, Weiss SB. The function of cytidine coenzymes in the biosynthesis of phospholipides. J Biol Chem 1956;222(1):193–214.PubMed
16.
Aoyama C, Liao H, Ishidate K. Structure and function of choline kinase isoforms in mammalian cells. Prog Lipid Res 2004;43(3):266–81.PubMedCrossRef
17.
Gallego-Ortega D, Ramirez de Molina A, Ramos MA, Valdes-Mora F, Barderas MG, Sarmentero-Estrada J, et al. Differential role of human choline kinase alpha and beta enzymes in lipid metabolism: implications in cancer onset and treatment. PLoS One 2009;4(11):e7819.PubMedCrossRef
18.
Aoyama C, Ohtani A, Ishidate K. Expression and characterization of the active molecular forms of choline/ethanolamine kinase-alpha and -beta in mouse tissues, including carbon tetrachloride-induced liver. Biochem J 2002;363(Pt 3):777–84.PubMedCrossRef
19.
Ramírez de Molina A, Rodríguez-González A, Gutiérrez R, Martínez-Piñeiro L, Sánchez J, Bonilla F, et al. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun 2002;296(3):580–3.PubMedCrossRef
20.
Hara T, Bansal A, DeGrado TR. Choline transporter as a novel target for molecular imaging of cancer. Mol Imaging 2006;5(4):498–509.PubMed
21.
Bertilsson H, Tessem MB, Flatberg A, Viset T, Gribbestad I, Angelsen A, et al. Changes in gene transcription underlying the aberrant citrate and choline metabolism in human prostate cancer samples. Clin Cancer Res 2012;18:3261–9.PubMedCrossRef
22.
Rodríguez-González A, Ramírez de Molina A, Fernández F, Ramos MA, del Carmen Núñez M, Campos J, et al. Inhibition of choline kinase as a specific cytotoxic strategy in oncogene-transformed cells. Oncogene 2003;22(55):8803–12.PubMedCrossRef
23.
Hernández-Alcoceba R, Saniger L, Campos J, Núñez MC, Khaless F, Gallo MA, et al. Choline kinase inhibitors as a novel approach for antiproliferative drug design. Oncogene 1997;15(19):2289–301.PubMedCrossRef
24.
Katz-Brull R, Degani H. Kinetics of choline transport and phosphorylation in human breast cancer cells; NMR application of the zero trans method. Anticancer Res 1996;16(3B):1375–80.PubMed
25.
Tew DG, Southan C, Rice SQ, Lawrence MP, Li H, Boyd HF, et al. Purification, properties, sequencing, and cloning of a lipoprotein-associated, serine-dependent phospholipase involved in the oxidative modification of low-density lipoproteins. Arterioscler Thromb Vasc Biol 1996;16(4):591–9.
26.
Vainio P, Gupta S, Ketola K, Mirtti T, Mpindi JP, Kohonen P, et al. Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer. Am J Pathol 2011;178:525–36.PubMedCrossRef
27.
Hara T, Bansal A, DeGrado T. Effect on hypoxia on the uptake of [methyl-3H]choline, [1-14C]acetate and [18F]FDG in cultured prostate cancer cells. Nucl Med Biol 2006;33:977–84.PubMedCrossRef
28.
Emonds KM, Swinnen JV, van Weerden WM, Vanderhoydonc F, Nuyts J, Mortelmans L, et al. Do androgens control the uptake of 18F-FDG, 11C-choline and 11C-acetate in human prostate cancer cell lines? Eur J Nucl Med Mol Imaging 2011;38:1842–53.PubMedCrossRef
29.
Jadvar H, Gurbuz A, Li X, Shahinian A, Conti PS. Choline autoradiography of human prostate cancer xenograft: effect of castration. Mol Imaging 2008;7:147–52.PubMed
30.
DeGrado TR, Coleman RE, Wang S, Baldwin SW, Orr MD, Robertson CN, et al. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res 2001;61:110–7.PubMed
31.
De Waele A, Van Binnebeek S, Mottaghy FM. Response assessment of hormonal therapy in prostate cancer by [11C]choline PET/CT. Clin Nucl Med 2010;35:701–3.PubMedCrossRef
32.
Beheshti M, Vali R, Waldenberger P, Fitz F, Nader M, Hammer J, et al. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT. Mol Imaging Biol 2009;11:446–54.PubMedCrossRef
33.
Giovacchini G, Picchio M, Coradeschi E, Scattoni V, Bettinardi V, Cozzarini C, et al. [(11)C]Choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy. Eur J Nucl Med Mol Imaging 2008;35:1065–73.PubMedCrossRef
34.
Fuccio C, Schiavina R, Castellucci P, Rubello D, Martorana G, Celli M, et al. Androgen deprivation therapy influences the uptake of 11C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study. Eur J Nucl Med Mol Imaging 2011;38:1985–9.PubMedCrossRef
35.
Price DT, Coleman E, Liao RP, Robertson CN, Polascik TJ, DeGrado TR. Comparison of [18F]fluorocholine and [18F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol 2002;168:273–80.PubMedCrossRef
36.
Giovacchini G, Picchio M, Coradeschi E, Bettinardi V, Gianolli L, Scattoni V, et al. Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging 2010;37(2):301–9.PubMedCrossRef
37.
Henninger B, Vesco P, Putzer D, Kendler D, Loizides A, Bale RJ, et al. [18F]choline positron emission tomography in prostate cancer patients with biochemical recurrence after radical prostatectomy: influence of antiandrogen therapy – a preliminary study. Nucl Med Commun 2012;33:889–94.PubMedCrossRef
38.
Mueller-Lisse UG, Swanson MG, Vigneron DB, Hricak H, Bessette A, Males RG, et al. Time-dependent effects of hormone-deprivation therapy on prostate metabolism as detected by combined magnetic resonance imaging and 3D magnetic resonance spectroscopic imaging. Magn Reson Med 2001;46(1):49–57.PubMedCrossRef
39.
Rinnab L, Mottaghy FM, Blumstein NM, Reske SN, Hautmann RE, Hohl K, et al. Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int 2007;100(4):786–93.PubMedCrossRef
40.
Reske SN, Blumstein NM, Glatting G. [11C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging 2008;35(1):9–17.PubMedCrossRef
41.
Krause BJ, Souvatzoglou M, Tuncel M, Herrmann K, Buck AK, Praus C, et al. The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 2008;35(1):18–23.PubMedCrossRef
42.
Cimitan M, Bortolus R, Morassut S, Canzonieri V, Garbeglio A, Baresic T, et al. [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 2006;33(12):1387–98.PubMedCrossRef
43.
Heinisch M, Dirisamer A, Loidl W, Stoiber F, Gruy B, Haim S, et al. Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml? Mol Imaging Biol 2006;8(1):43–8.PubMedCrossRef
44.
Husarik DB, Miralbell R, Dubs M, John H, Giger OT, Gelet A, et al. Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging 2008;35(2):253–63.PubMedCrossRef
Metadaten
Titel
Influence of androgen deprivation therapy on choline PET/CT in recurrent prostate cancer
verfasst von
Rutger J. Dost
Andor W. J. M. Glaudemans
Anthonius J. Breeuwsma
Igle J. de Jong
Publikationsdatum
01.07.2013
Verlag
Springer-Verlag
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe Sonderheft 1/2013
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-013-2398-7

Weitere Artikel der Sonderheft 1/2013

European Journal of Nuclear Medicine and Molecular Imaging 1/2013 Zur Ausgabe

Editorial

Prostate cancer imaging

Review Article

Role of choline PET/CT in guiding target volume delineation for irradiation of prostate cancer

Review Article

Metabolomic imaging of prostate cancer with magnetic resonance spectroscopy and mass spectrometry

Review Article

Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations

Review Article

Challenges in accurate registration of 3-D medical imaging and histopathology in primary prostate cancer

Original Article

Comparison of 18F-FACBC and 11C-choline PET/CT in patients with radically treated prostate cancer and biochemical relapse: preliminary results